{"title":"Psychosocial Distress, Depression and Burden Among Primary Caregivers of Children With Steroid-Sensitive Nephrotic Syndrome.","authors":"Mritunjay Kumar, Rashmi Kumari, Rashmi Shukla, Namita Mishra, Amit Shukla, Bimlesh Prasad","doi":"10.1007/s13312-025-00132-3","DOIUrl":"https://doi.org/10.1007/s13312-025-00132-3","url":null,"abstract":"<p><strong>Objective: </strong>This study assessed the psychological distress, depression, and burden among primary caregivers of children with steroid-sensitive nephrotic syndrome (SSNS) and explored its association with disease severity and patient/caregiver demographics.</p><p><strong>Methods: </strong>Psychological assessment of primary caregivers of children aged 6 months to 15 years with SSNS was performed using General Health Questionnaire-12 for psychological distress, Beck Depression Inventory for depression, and Zarit Burden Interview-6 for caregiver burden.</p><p><strong>Results: </strong>Out of 72 eligible caregivers, 60 were included. Severe depression, severe psychological distress, and significant caregiver burden were observed in 38.3%, 30%, and 61.7% of primary caregivers, respectively. Steroid-dependent nephrotic syndrome (SDNS) and disease duration over 24 months increased severe psychological distress. Risk factors for caregiver depression included child < 7 years, female gender, frequently relapsing nephrotic syndrome (FRNS)/SDNS, steroid use > 6 months, > 4 relapses, and prior hospitalization. Caregiver burden was higher in younger age, FRNS/SDNS, hospitalization, and lower middle socio-economic status.</p><p><strong>Conclusion: </strong>Caregivers of children with SSNS experience significant psychological distress, depression, and financial burden.</p>","PeriodicalId":13291,"journal":{"name":"Indian pediatrics","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Implications of Musculoskeletal Manifestations in Acute Lymphoblastic Leukemia: A Decade's Experience from a Referral Center in Southern India.","authors":"Konsam Samuel Lyngdoh, Pandya Dhruti, Sidharth Totadri, Somdipa Pal, Jyothi Munireddy, Vandana Bharadwaj, Anand Prakash","doi":"10.1007/s13312-025-00064-y","DOIUrl":"10.1007/s13312-025-00064-y","url":null,"abstract":"<p><strong>Objective: </strong>Children with acute lymphoblastic leukemia (ALL) with musculoskeletal (MSK) manifestations may be misdiagnosed as juvenile idiopathic arthritis (JIA). The present study compared the baseline parameters and survival outcomes in patients with ALL with and without MSK symptoms.</p><p><strong>Methods: </strong>A retrospective chart review of children aged < 18 years diagnosed with ALL was performed. Based on contemporary parameters, the patients were stratified into standard-risk (SR), intermediate-risk (IR), and high-risk (HR) groups. Clinical and laboratory features and survival outcomes were compared between ALL patients with and without MSK symptoms.</p><p><strong>Results: </strong>Out of 255 participants, 67 (26%) had MSK manifestations; of these, 9 were pretreated for JIA with glucocorticoids/methotrexate. Patients with MSK manifestations had a longer median duration of symptoms before diagnosis (4 vs 2 weeks, P < 0.001), and a higher median platelet count (53 × 10<sup>9</sup>/L vs. 28 × 10<sup>9</sup>/L, P = 0.002). The 3-year event-free survival (EFS) for patients with MSK and without MSK manifestations were 84.4 ± 5.2% and 78.9 ± 3.4% (P = 0.900). All 9 pretreated patients received an IR/HR protocol (4 were SR if not for the pretreatment as JIA).</p><p><strong>Conclusion: </strong>Patients with ALL with MSK manifestations have more preserved blood counts and a longer duration of symptoms before diagnosis. Pretreatment of children with ALL misdiagnosed as JIA with glucocorticoids/methotrexate can delay the diagnosis, confound the risk stratification, and upstage the risk group requiring administration of more toxic chemotherapy than necessary otherwise.</p>","PeriodicalId":13291,"journal":{"name":"Indian pediatrics","volume":" ","pages":"489-494"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Indian pediatricsPub Date : 2025-07-01Epub Date: 2025-05-22DOI: 10.1007/s13312-025-00095-5
Kanya Mukhopadhyay
{"title":"Nourishing the Future Generations: Role of Maternal Education, Empowerment and Autonomy.","authors":"Kanya Mukhopadhyay","doi":"10.1007/s13312-025-00095-5","DOIUrl":"10.1007/s13312-025-00095-5","url":null,"abstract":"","PeriodicalId":13291,"journal":{"name":"Indian pediatrics","volume":" ","pages":"547-548"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Indian pediatricsPub Date : 2025-07-01Epub Date: 2025-06-04DOI: 10.1007/s13312-025-00109-2
Ashima Mehta, Praveen Suman, Imran Noorani
{"title":"Accuracy of 'Communication and Symbolic Behaviour Scales Developmental Profile-Infant Toddler Checklist' for Screening Communication Delay in Children Aged 6-24 Months Referred to a Child Developmental Clinic.","authors":"Ashima Mehta, Praveen Suman, Imran Noorani","doi":"10.1007/s13312-025-00109-2","DOIUrl":"10.1007/s13312-025-00109-2","url":null,"abstract":"<p><strong>Objective: </strong>To assess the accuracy of the Communication and Symbolic Behaviour Scales Developmental Profile-Infant Toddler Checklist (CSBS-ITC) for screening communication delay in children aged 6-24 months.</p><p><strong>Method: </strong>This hospital-based observational cross-sectional study included 200 children aged 6-24 months of either sex attending the child development clinic. Participants were categorized into high- and low-risk groups based on perinatal and neurological risk factors. The CSBS-ITC was administered to parents, followed by a standardized developmental assessment using the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III). Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of CSBS-ITC were calculated.</p><p><strong>Results: </strong>Communication concerns were identified in 69% of children using the CSBS-ITC, and among these, 65% was confirmed to have language delays on the BSID-III assessment. CSBS-ITC demonstrated a high sensitivity (94%) and specificity (82%), with a positive predictive value of 87% and a negative predictive value of 80%.</p><p><strong>Conclusion: </strong>CSBS-ITC is a useful tool for screening communication delay in high-risk children aged 6-24 months, and the tool exhibits good screening accuracy.</p>","PeriodicalId":13291,"journal":{"name":"Indian pediatrics","volume":" ","pages":"511-515"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Indian pediatricsPub Date : 2025-07-01Epub Date: 2025-06-18DOI: 10.1007/s13312-025-00113-6
Rıza Taner Baran, Gamze Çelmeli, Ceyhun Tıkız, Arif Önder, Özge Gizli Çoban
{"title":"Gynecomastia in Adolescents: Impact on Mental Health and Body Image.","authors":"Rıza Taner Baran, Gamze Çelmeli, Ceyhun Tıkız, Arif Önder, Özge Gizli Çoban","doi":"10.1007/s13312-025-00113-6","DOIUrl":"10.1007/s13312-025-00113-6","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore depression, anxiety, and body image issues in adolescents with gynecomastia.</p><p><strong>Methods: </strong>Forty adolescents aged 12-18 years diagnosed with gynecomastia and 40 age-matched volunteer healthy adolescent boys were enrolled. Mental health issues were assessed using Beck Anxiety Inventory (BAI), Social Appearance Anxiety Scale (SAAS), the Children's Depression Inventory (CDI), Body Cathexis Scale (BCS), and the Brief Fear of Negative Evaluation Scale (BFNE).</p><p><strong>Results: </strong>The mean (SD) BFNE [29.82 (10.08) vs. 24.62 (9.96); P = 0.023] and the SAAS [42.27 (18.15) vs. 31.32 (14.71); P = 0.004] scales were significantly higher in the patient group compared to controls. A significant negative correlation was observed between age and SAAS (r = - 0.349), and age and BFNE (r = - 0.522). A significant positive correlation was seen between SAAS and the grade of gynecomastia (r = 0.479).</p><p><strong>Conclusion: </strong>Early psychological support is needed to reduce distress in adolescents with gynecomastia.</p>","PeriodicalId":13291,"journal":{"name":"Indian pediatrics","volume":" ","pages":"521-524"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Indian pediatricsPub Date : 2025-07-01Epub Date: 2025-04-22DOI: 10.1007/s13312-025-00075-9
Vykuntaraju K Gowda, Halima Simin, Uddhava V Kinhal, G V Basavaraja, K S Sanjay
{"title":"Cannabidiol in Drug-Resistant Epilepsy (DRE) in Children: A Retrospective Study.","authors":"Vykuntaraju K Gowda, Halima Simin, Uddhava V Kinhal, G V Basavaraja, K S Sanjay","doi":"10.1007/s13312-025-00075-9","DOIUrl":"10.1007/s13312-025-00075-9","url":null,"abstract":"<p><strong>Objectives: </strong>To describe the effectiveness and tolerability of cannabidiol (CBD) in children with drug-resistant epilepsy (DRE).</p><p><strong>Methods: </strong>Records of children with DRE who received CBD for at least six months were reviewed. Reduction in seizure frequency [complete (> 90%), partial (30-90%), no response (< 30%)], parent reported adverse effects and discontinuation of CBD, if any, were noted.</p><p><strong>Results: </strong>Records of 50 children with DRE (Lennox-Gastaut syndrome 32, Dravet syndrome 4, and Tuberous sclerosis complex 2), mean (SD) age 7.8 (4.3) years were reviewed. Complete, partial, and no response to CBD was seen in 10, 18 and 14 children; 8 became seizure-free. Eight children discontinued treatment due to lack of efficacy (n = 4), by increased adverse effects (n = 3) and aggravation of seizures (n = 1). Adverse effects were noted in 22 (44%), none required hospitalization.</p><p><strong>Conclusion: </strong>Cannabidiol is a useful and safe add-on drug in children with DRE.</p>","PeriodicalId":13291,"journal":{"name":"Indian pediatrics","volume":" ","pages":"501-505"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Risk Stratification-Based Therapy for Children with E-beta Thalassemia: A 20-Year Follow-Up Study.","authors":"Kavitha Ganesan, Suresh Duraisamy, Anupama Nair, Vijayshree Muthukumar, Anurag Nalla Reddy, Minakshi Balwani, Nithya Seshadri, Ramya Uppuluri, Revathi Raj","doi":"10.1007/s13312-025-00089-3","DOIUrl":"10.1007/s13312-025-00089-3","url":null,"abstract":"<p><strong>Objective: </strong>To present risk stratification-based follow-up of children with E-beta thalassemia.</p><p><strong>Methods: </strong>Children with E-beta thalassemia between August 2002 and August 2022 were classified as mild, moderate, or severe disease using Mahidol scoring. Children in the moderate group with < 20 or ≥ 20 nucleated red blood cells (nRBCs) per 100 white blood cells were clubbed with mild or severe phenotype, respectively. Children with mild/moderate severity received hydroxyurea (HU) and those with severe disease received regular transfusions.</p><p><strong>Results: </strong>Out of 104 children (median age of onset 3.5 years), 30 (29%), 46 (44%), and 28 (27%) were categorized as mild, moderate, and severe disease, at initial presentation. Based on nRBC count, 27 and 19 children in moderate category were recategorized as mild to moderate and moderate to severe. Fifty-six, 19, and 29 children received HU, transfusions with HU, and monthly transfusion and chelation, respectively. At a median follow-up of 8 years, 67/93 (72%) children classified as \"mild to moderate\" remained well on HU, and 26/93 (28%) children classified as \"moderate to severe\" remained on regular transfusions.</p><p><strong>Conclusion: </strong>Using nRBCs in addition to Mahidol scoring can serve as a useful tool to individualize therapy.</p>","PeriodicalId":13291,"journal":{"name":"Indian pediatrics","volume":" ","pages":"506-510"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Serum Immunoglobulin Levels in Children with Acute Lymphoblastic Leukemia During Maintenance Chemotherapy and its Association with Severe Febrile Illness.","authors":"Maharshi Trivedi, Priyakumari Thankamony, Manjusha Nair, Binitha Rajeswari, Guruprasad Chellappan Sojamani, Shwetha Seetharam, Prasanth Varikkattu Rajendran, Jagathnath Krishna","doi":"10.1007/s13312-025-00034-4","DOIUrl":"10.1007/s13312-025-00034-4","url":null,"abstract":"<p><strong>Objective: </strong>To determine the proportion of children with acute lymphoblastic leukemia (ALL) with hypoglobulinemia during maintenance chemotherapy and to determine its association with severe febrile illnesses.</p><p><strong>Methods: </strong>Children with ALL receiving maintenance chemotherapy were prospectively recruited and serum immunoglobulin levels (IgG, IgM, IgA) were measured by turbidimetric method. Children were followed up for severe febrile illnesses for 6 months or till the completion of treatment.</p><p><strong>Results: </strong>We enrolled 199 children with mean (SD) age 82.03 (39.34) months; 58, 52, 47, and 42 children had received 0-6, 7-12, 13-18 and 19-24 months of maintenance chemotherapy, respectively. Hypo-IgG, hypo-IgA, and hypo-IgM were seen in 56.8%, 80.4%, and 86.4% of children. 91 (45.7%) children developed 147 episodes of severe febrile illness. Older age (> 5 years) was associated with decreased risk [odds ratio 95% CI] of hypo-IgG [0.540 (0.297, 0.982), P = 0.044], hypo-IgA [0.030 (0.011, 0.088), P = 0.001], and hypo-IgM [0.323 (0.117, 0.894), P = 0.030] and female gender had decreased risk of hypo-IgG (0.539 (0.305, 0.953), P = 0.033). Older age decreased the risk [0.585 (0.328, 1.041), P = 0.014] and girls were at increased risk [(1.118, 3.488), P = 0.019] of severe febrile illness. Hypoglobulinemia did not increase the risk of severe febrile illness.</p><p><strong>Conclusion: </strong>Hypoglobulinemia was not found to be an independent risk factor for severe febrile illnesses in children with ALL receiving maintenance chemotherapy.</p>","PeriodicalId":13291,"journal":{"name":"Indian pediatrics","volume":" ","pages":"482-488"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}